189 results on '"Gooderham, Melinda J."'
Search Results
2. Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis
3. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
4. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2
5. Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial
6. Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel
7. Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial
8. Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for moderate-to-severe acne: Efficacy and safety results from two randomized phase 3 trials
9. Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
10. Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
11. Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel
12. Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology
13. Practical Management of Patients with Atopic Dermatitis on Dupilumab
14. Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD
15. Real‐world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study.
16. Phosphodiesterase-4 Inhibition in the Management of Psoriasis.
17. Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis and comorbid allergies.
18. Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials.
19. Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
20. Efficacy of prolonged ruxolitinib cream treatment for vitiligo among patients with limited or no initial response at 6 months.
21. Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
22. Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice.
23. Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: A Canadian perspective.
24. Dupilumab: A review of its use in the treatment of atopic dermatitis
25. Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: Randomized phase 2 study.
26. 52876 Relationships Among Abrocitinib Treatment, Itch, Skin Clearance, Anxiety, and Depression: A Mediation Modeling Analysis.
27. 51876 Impact of Long-Term Abrocitinib Treatment on Patient-Reported Outcomes and Quality of Life for Approximately 2 Years in Patients With Moderate-to-Severe Atopic Dermatitis: An Interim Analysis of JADE EXTEND, a Long-Term Extension Study.
28. 52853 Impact of Baseline Disease Severity on the Long-Term Efficacy of Abrocitinib Treatment in Patients With Moderate-To-Severe Atopic Dermatitis: Interim Analysis of the Long-Term Extension JADE EXTEND Study.
29. 53959 Treatment With Upadacitinib Increases the Achievement of Minimal Disease Activity Among Patients With Moderate-to-Severe Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1 and Measure Up 2).
30. 50865 Efficacy of Step-up Abrocitinib Treatment in Combination With Topical Medicated Therapy for Treating Atopic Dermatitis Flares: A Post Hoc Analysis of the JADE REGIMEN Trial.
31. 403 Achievement of minimal disease activity is associated with improvements in symptoms, quality of life and treatment satisfaction in patients with atopic dermatitis.
32. Management of moderate‐to‐severe plaque psoriasis with biologics: A treat‐to‐target position paper.
33. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
34. Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study.
35. Validation of the skin pain numerical rating scale of the Pruritus and Symptoms Assessment for Atopic Dermatitis for adults and adolescents with moderate-to-severe atopic dermatitis.
36. Real-world use and effectiveness of upadacitinib in adults and adolescents with atopic dermatitis: preliminary analysis of the real-world multicountry AD-VISE study.
37. Practice Patterns of Palmoplantar Pustulosis: Patient Demographics and Treatment Options.
38. Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab.
39. Safety of Janus kinase (JAK) inhibitors in the short‐term treatment of atopic dermatitis.
40. Could it be gluten? Additional skin conditions associated with celiac disease.
41. Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis.
42. A soy protein isolate rich in genistein and daizein and its effects on plasma isoflavone concentrations, platelet aggregation, blood lipids and fatty acid composition of plasma phospholipid in normal men
43. Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study.
44. Improvement of granulomatous skin conditions with tofacitinib in three patients: A case report.
45. Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.
46. Considerations for defining and diagnosing generalized pustular psoriasis.
47. Psoriasis Prevalence and Severity by Expert Elicitation.
48. Phosphodiesterase-4 Inhibition in Psoriasis.
49. Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel.
50. Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.